KU Leuven

ImCyse SA is a clinical-stage biopharmaceutical company based in Liège, Belgium, that specializes in developing active immunotherapies aimed at treating and preventing severe chronic autoimmune diseases linked to immune system disruptions. Founded in 2010, ImCyse utilizes a unique technology platform that focuses on the administration of Imotopes™, specifically modified peptides that generate cytolytic CD4 T-cells. These T-cells selectively eliminate antigen-presenting cells and autoantigen-specific lymphocytes, targeting the underlying causes of diseases like type 1 diabetes and multiple sclerosis. ImCyse's innovative approach not only aims to provide therapeutic alternatives where none exist but also seeks to cure patients without compromising their immune defenses. The company has demonstrated proof of concept across several indications and has successfully completed its first clinical trial for type 1 diabetes, yielding promising results while developing additional Imotopes™ for various autoimmune conditions.

reMYND NV is a biotechnology company based in Leuven, Belgium, focused on developing disease-modifying treatments for Alzheimer’s, Parkinson’s, diabetes, and other protein-misfolding disorders. The company is advancing several investigational compounds, including ReS19-T for Alzheimer’s and ReS39 for diabetes, as well as ReS3-T, which targets neuronal hyperactivity associated with Alzheimer’s and epilepsy. Additionally, reMYND operates a phenotypic screening platform aimed at discovering small molecule treatments that mitigate the toxicity of misfolded proteins such as Tau and Synuclein. The company also functions as a contract research organization (CRO), providing services that assess the in-vivo characteristics and effects of experimental therapies using proprietary mouse models. This CRO capability has enabled reMYND to support various pharmaceutical clients, including major companies in the United States, Europe, and Japan, by delivering critical proof-of-concept data for drugs in clinical development. Established in 2002, reMYND is committed to addressing the challenges posed by protein misfolding diseases through innovative research and development.

ViroVet is an innovative company focused on developing groundbreaking technologies to combat viral diseases in livestock, particularly through antiviral drugs targeting respiratory disease complexes and novel vaccines for swine. The livestock industry, valued at over 100 billion euros, faces significant financial losses due to viral diseases, which threaten global animal protein supplies. ViroVet aims to supply livestock producers, national governments, and international organizations with comprehensive solutions that can be used independently or alongside existing vaccines and biosecurity measures. With the growing world population and increased demand for protein, the risk of viral disease spread in densely populated livestock environments is rising. ViroVet has garnered support from key opinion leaders in livestock medicine, who recognize the potential of its products to reduce antibiotic use and transform the industry. Through its innovative approach, ViroVet addresses urgent challenges posed by endemic and epizootic viral diseases, ultimately aiming to enhance the resilience of the livestock sector.

Montis Biosciences is a biotechnology company based in Meise, Belgium, established in 2020. It focuses on developing immune-oncology therapeutics that address the relationship between vascular dysfunction and immune suppression in the treatment of solid tumors. The company has developed a target screening and assay platform that explores the interactions between tumor endothelial cells and perivascular macrophages. By understanding these cellular interactions, Montis Biosciences aims to create novel therapeutic strategies that enhance immune reactions against solid tumors, offering a new perspective for targeted cancer treatment.

MyCellHub is a pre-startup from KULeuven focused on transforming cell production processes within the biotherapeutics industry. The company has developed a regulatory-compliant software-as-a-service (SaaS) platform that streamlines data management and analytics for laboratory and cleanroom workflows. This platform enables users to capture real-time data from multiple sources, integrating seamlessly with existing enterprise resource planning (ERP) systems. By providing actionable insights through cell culture-specific process analytics, MyCellHub enhances manufacturing efficiency while ensuring regulatory compliance through features like real-time audit trails and automated batch records. The company's solutions aim to optimize data reporting and management, ultimately improving the overall productivity of manufacturing processes in the sector.

nextAuth specializes in mobile-based user authentication software that enhances security and user experience by eliminating the need for usernames and passwords. The company's innovative approach leverages advanced cryptography to provide strong multi-factor authentication, allowing users to securely log into web portals or applications with ease. Additionally, nextAuth's technology facilitates the signing of documents and transactions in compliance with advanced electronic signature requirements. By focusing on usability and security, nextAuth enables a seamless authentication process that prioritizes both safety and convenience for users.

reMYND NV is a biotechnology company based in Leuven, Belgium, focused on developing disease-modifying treatments for Alzheimer’s, Parkinson’s, diabetes, and other protein-misfolding disorders. The company is advancing several investigational compounds, including ReS19-T for Alzheimer’s and ReS39 for diabetes, as well as ReS3-T, which targets neuronal hyperactivity associated with Alzheimer’s and epilepsy. Additionally, reMYND operates a phenotypic screening platform aimed at discovering small molecule treatments that mitigate the toxicity of misfolded proteins such as Tau and Synuclein. The company also functions as a contract research organization (CRO), providing services that assess the in-vivo characteristics and effects of experimental therapies using proprietary mouse models. This CRO capability has enabled reMYND to support various pharmaceutical clients, including major companies in the United States, Europe, and Japan, by delivering critical proof-of-concept data for drugs in clinical development. Established in 2002, reMYND is committed to addressing the challenges posed by protein misfolding diseases through innovative research and development.

Loci Orthopaedics Limited, based in Upper Newcastle, Ireland, specializes in developing innovative medical technologies to address significant unmet clinical needs in orthopedics. Founded in 2017, the company focuses on creating surgical implants, particularly the InDx implant, which is designed to treat arthritis in the thumb base joint. This implant uniquely mimics the natural motions of the thumb joint, offering a less invasive and easier insertion method compared to existing surgical options. Additionally, Loci Orthopaedics is known for its Osteoanchor surface architecture, which is based on evidence-based designs, enabling clinicians to effectively address challenges in orthopedic extremities.

UgenTec, based in Hasselt, is a rapidly growing company that specializes in developing software for molecular diagnostics. The company offers an independent diagnostic platform that supports molecular laboratories in analyzing DNA through real-time PCR technology. UgenTec's software automates the interpretation of PCR assays, enabling lab technicians to significantly reduce analysis time from 1.5 hours to just 3 minutes without the need for extensive training. This advancement not only boosts laboratory efficiency but also enhances diagnostic reliability for patients. UgenTec's innovative approach has garnered multiple awards and recognitions, reflecting its commitment to improving laboratory workflows and outcomes in the field of molecular diagnostics.

VersaSense allows you to reliably connect any asset to any cloud analytics platform, and manage that infrastructure.

Porphyrio NV is a Belgium-based company that specializes in providing intelligent management systems for poultry farming, focusing on egg and broiler production. Its flagship products, Lay-Insight and Broiler-Insight, are designed to assist farm managers in the day-to-day operations by utilizing real-time data and advanced statistical algorithms. These systems enhance operational efficiency by transforming sensor data into actionable insights, enabling proactive decision-making and predictive analysis. Porphyrio's technology also includes features such as access control and video surveillance, and it can integrate with external ERP systems. The company serves a diverse range of poultry, including breeders, broilers, laying hens, and turkeys. As of November 2018, Porphyrio operates as a subsidiary of Evonik Industries AG.